Genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants: supplemental material

Drug-induced long QT syndrome (diLQTS) is an adverse effect of many commonly prescribed drugs, and
it can increase the risk for lethal ventricular arrhythmias. Genetic variants in pharmacodynamic genes
have been associated with diLQTS, but the strength of the evidence for each of those variants has not yet
been evaluated. Therefore, the purpose of this review was to evaluate the strength of the evidence for
pharmacodynamic genetic variants associated with diLQTS using a novel, semiquantitative scoring system
modified from the approach used for congenital LQTS. KCNE1-D85N and KCNE2-T8A had definitive and
strong evidence for diLQTS, respectively. The high level of evidence for these variants supports current
consideration as risk factors for patients that will be prescribed a QT-prolonging drug.